Skip to content
Teethgrinder – Lifestyle
Author:
Medicus Pharma Ltd
Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate
March 30, 2026
Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset
March 27, 2026
Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan
March 26, 2026
Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst
March 18, 2026
←
Previous Page
1
2
3